75 related articles for article (PubMed ID: 35608632)
1. PFKM inhibits doxorubicin-induced cardiotoxicity by enhancing oxidative phosphorylation and glycolysis.
Zhou M; Sun X; Wang C; Wang F; Fang C; Hu Z
Sci Rep; 2022 Jul; 12(1):11684. PubMed ID: 35804014
[TBL] [Abstract][Full Text] [Related]
2. Small molecule drug discovery for glioblastoma treatment based on bioinformatics and cheminformatics approaches.
Feng L; Zhu S; Ma J; Huang J; Hou X; Qiu Q; Zhang T; Wan M; Li J
Front Pharmacol; 2024; 15():1389440. PubMed ID: 38681202
[No Abstract] [Full Text] [Related]
3. Mitotic Functions and Characters of KIF11 in Cancers.
Gao W; Lu J; Yang Z; Li E; Cao Y; Xie L
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672404
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Warburg Effect in Cancer: Where Do We Stand?
Barba I; Carrillo-Bosch L; Seoane J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542116
[TBL] [Abstract][Full Text] [Related]
5. Digging deeper for new targets in bevacizumab resistance.
Lawler SE
Neuro Oncol; 2023 Feb; 25(2):261-262. PubMed ID: 36516222
[No Abstract] [Full Text] [Related]
6. Use of bevacizumab in recurrent glioblastoma.
Ghiaseddin A; Peters KB
CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439
[TBL] [Abstract][Full Text] [Related]
7. Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy.
Lim YC; Jensen KE; Aguilar-Morante D; Vardouli L; Vitting-Seerup K; Gimple RC; Wu Q; Pedersen H; Elbaek KJ; Gromova I; Ihnatko R; Kristensen BW; Petersen JK; Skjoth-Rasmussen J; Flavahan W; Rich JN; Hamerlik P
Neuro Oncol; 2023 Feb; 25(2):248-260. PubMed ID: 35608632
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
9. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
10. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
[TBL] [Abstract][Full Text] [Related]
11. Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.
Simon T; Pinioti S; Schellenberger P; Rajeeve V; Wendler F; Cutillas PR; King A; Stebbing J; Giamas G
Mol Cancer; 2018 Aug; 17(1):132. PubMed ID: 30165850
[TBL] [Abstract][Full Text] [Related]
12. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
13. Local Anesthetics and Recurrence after Cancer Surgery-What's New? A Narrative Review.
Müller SD; Ziegler JSH; Piegeler T
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670434
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
